{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:49:36Z","timestamp":1791575376813,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00248157"],"award-info":[{"award-number":["RS-2023-00248157"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["IITP-2024-RS-2024-00438239"],"award-info":[{"award-number":["IITP-2024-RS-2024-00438239"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Research on Guillain-Barr\u00e9 syndrome (GBS) as a neurological adverse effect of vaccines on a global scale is scarce, highlighting the need for further investigation to evaluate its long-term impact and associated risk factors comprehensively. Hence, this study aims to assess the global burden of vaccine-associated GBS and its associated vaccines. This study utilized data from VigiBase, the World Health Organization global database of adverse event reports of medicines and vaccines, encompassing the period from 1967 to 2023 (total reports, <jats:italic>n<\/jats:italic>\u2009=\u2009131,255,418) to investigate vaccine-associated GBS. Reported odds ratios (ROR) and information components (IC) were analyzed to assess the association between 19 vaccines and the occurrence of vaccine-associated GBS over 170 countries. We identified 15,377 (8072 males [52.49%]) reports of vaccine-associated GBS among 22,616 reports of all drugs-cause GBS from 1978 to 2023. Cumulative reports of vaccine-associated GBS have been increasing steadily over time, with a notable surge observed since the commencement of COVID-19 vaccines administration in 2020. Most vaccines showed significant associations with GBS such as Ad5-vectored COVID-19 vaccines (ROR, 14.88; IC, 3.66), COVID-19 mRNA vaccines (ROR, 9.66; IC, 2.84), and inactivated whole-virus COVID-19 vaccines (ROR, 3,29; IC 1.69). Influenza vaccines showed the highest association (ROR, 77.91; IC 5.98). Regarding age-and sex-specific risks, the association remained similar regardless of sex, with an increased association observed with advancing age. The mean time to onset was 5.5 days. Amid the COVID-19 pandemic, the reports of GBS surged in response to widespread COVID-19 vaccination. Nonetheless, COVID-19 vaccines exhibited the lowest association compared to other vaccines. Vigilance for at least one-week post-vaccination is crucial, particularly for older adults. Further research is warranted to elucidate the underlying mechanisms linking vaccines and GBS.<\/jats:p>","DOI":"10.1038\/s41598-024-74729-2","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T02:02:27Z","timestamp":1729303347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Global burden of vaccine-associated Guillain-Barr\u00e9 syndrome over 170 countries from 1967 to 2023"],"prefix":"10.1038","volume":"14","author":[{"given":"Yi Deun","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woojin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinseok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiseung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Udeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Geun","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"74729_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/s1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302. https:\/\/doi.org\/10.1016\/s1473-3099(22)00320-6 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"74729_CR2","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41562-024-01895-8","volume":"8","author":"S Kim","year":"2024","unstructured":"Kim, S. et al. Short- and long-term neuropsychiatric outcomes in long COVID in South Korea and Japan. Nat. Hum. Behav. 8, 1530\u20131544. https:\/\/doi.org\/10.1038\/s41562-024-01895-8 (2024).","journal-title":"Nat. Hum. Behav."},{"key":"74729_CR3","doi-asserted-by":"publisher","unstructured":"Chakraborty, C., Bhattacharya, M. & Dhama, K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. Vaccines (Basel). 11\u00a0https:\/\/doi.org\/10.3390\/vaccines11030682 (2023).","DOI":"10.3390\/vaccines11030682"},{"key":"74729_CR4","doi-asserted-by":"publisher","first-page":"e29591","DOI":"10.1002\/jmv.29591","volume":"96","author":"HG Woo","year":"2024","unstructured":"Woo, H. G. et al. Global burden of vaccine-associated multiple sclerosis, 1967\u20132022: a comprehensive analysis of the international pharmacovigilance database. J. Med. Virol. 96, e29591. https:\/\/doi.org\/10.1002\/jmv.29591 (2024).","journal-title":"J. Med. Virol."},{"key":"74729_CR5","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone, M. et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat. Med. 27, 2144\u20132153. https:\/\/doi.org\/10.1038\/s41591-021-01556-7 (2021).","journal-title":"Nat. Med."},{"key":"74729_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.7326\/m23-1831","volume":"177","author":"MS Kim","year":"2024","unstructured":"Kim, M. S. et al. Long-term autoimmune inflammatory rheumatic outcomes of COVID-19: a binational cohort study. Ann. Intern. Med. 177, 291\u2013302. https:\/\/doi.org\/10.7326\/m23-1831 (2024).","journal-title":"Ann. Intern. Med."},{"key":"74729_CR7","doi-asserted-by":"publisher","first-page":"8280","DOI":"10.26355\/eurrev_202309_33588","volume":"27","author":"J Song","year":"2023","unstructured":"Song, J. et al. National prevalence and determinants of COVID-19 vaccine hesitancy during the initial phase pandemic. Eur. Rev. Med. Pharmacol. Sci. 27, 8280\u20138290. https:\/\/doi.org\/10.26355\/eurrev_202309_33588 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"74729_CR8","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.54724\/lc.2023.e9","volume":"3","author":"HJ Kim","year":"2023","unstructured":"Kim, H. J., Park, H., Yon, D. K. & Rahmati, M. National trends in influenza vaccination coverage rates in South Korea between 2007\u20132020, including the COVID-19 pandemic: a longitudinal nationwide serial study. Life Cycle 3, e9. https:\/\/doi.org\/10.54724\/lc.2023.e9 (2023).","journal-title":"Life Cycle"},{"key":"74729_CR9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/s0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila, N., Lehmann, H. C. & Kuwabara, S. Guillain-Barr\u00e9 syndrome. Lancet 397, 1214\u20131228. https:\/\/doi.org\/10.1016\/s0140-6736(21)00517-1 (2021).","journal-title":"Lancet"},{"key":"74729_CR10","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1016\/j.vaccine.2018.05.119","volume":"37","author":"N Principi","year":"2019","unstructured":"Principi, N. & Esposito, S. Vaccine-preventable diseases, vaccines and Guillain-Barre\u2019 syndrome. Vaccine 37, 5544\u20135550. https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.119 (2019).","journal-title":"Vaccine"},{"key":"74729_CR11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","volume":"181","author":"R Goud","year":"2021","unstructured":"Goud, R. et al. Risk of Guillain-Barr\u00e9 Syndrome following recombinant zoster vaccine in medicare beneficiaries. JAMA Intern. Med. 181, 1623\u20131630. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6227 (2021).","journal-title":"JAMA Intern. Med."},{"key":"74729_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist, M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inform. J. 42, 409\u2013419. https:\/\/doi.org\/10.1177\/009286150804200501 (2008).","journal-title":"Drug Inform. J."},{"key":"74729_CR13","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.54724\/lc.2022.e13","volume":"2","author":"C Min","year":"2022","unstructured":"Min, C. The importance of a World Health Organization international pharmacovigilance database (VigiBase): novel methods for safety monitoring and surveillance of medical products. Life Cycle 2, e13. https:\/\/doi.org\/10.54724\/lc.2022.e13 (2022).","journal-title":"Life Cycle"},{"key":"74729_CR14","doi-asserted-by":"publisher","first-page":"e29682","DOI":"10.1002\/jmv.29682","volume":"96","author":"YD Jeong","year":"2024","unstructured":"Jeong, Y. D. et al. Global and regional burden of vaccine-associated facial paralysis, 1967\u20132023: findings from the WHO international pharmacovigilance database. J. Med. Virol. 96, e29682. https:\/\/doi.org\/10.1002\/jmv.29682 (2024).","journal-title":"J. Med. Virol."},{"key":"74729_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/all.16304","author":"YD Jeong","year":"2024","unstructured":"Jeong, Y. D. et al. Global burden of vaccine-associated angioedema and their related vaccines, 1967\u20132023: findings from the global pharmacovigilance database. Allergyhttps:\/\/doi.org\/10.1111\/all.16304 (2024).","journal-title":"Allergy"},{"key":"74729_CR16","doi-asserted-by":"publisher","first-page":"e21376","DOI":"10.7759\/cureus.21376","volume":"14","author":"S Dutta","year":"2022","unstructured":"Dutta, S. et al. Analysis of neurological adverse events reported in VigiBase from COVID-19 vaccines. Cureus 14, e21376. https:\/\/doi.org\/10.7759\/cureus.21376 (2022).","journal-title":"Cureus"},{"key":"74729_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF03256752","volume":"23","author":"P Mozzicato","year":"2009","unstructured":"Mozzicato, P. MedDRA. Pharm. Med. 23, 65\u201375. https:\/\/doi.org\/10.1007\/BF03256752 (2009).","journal-title":"Pharm. Med."},{"key":"74729_CR18","doi-asserted-by":"publisher","first-page":"14293","DOI":"10.1038\/s41598-021-93750-3","volume":"11","author":"S Park","year":"2021","unstructured":"Park, S. et al. Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase. Sci. Rep. 11, 14293. https:\/\/doi.org\/10.1038\/s41598-021-93750-3 (2021).","journal-title":"Sci. Rep."},{"key":"74729_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","volume":"157","author":"DD Nguyen","year":"2021","unstructured":"Nguyen, D. D. et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 157, 35\u201342. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3385 (2021).","journal-title":"JAMA Dermatol."},{"key":"74729_CR20","doi-asserted-by":"publisher","first-page":"e29693","DOI":"10.1002\/jmv.29693","volume":"96","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: findings with critical reanalysis from the WHO pharmacovigilance database. J. Med. Virol. 96, e29693. https:\/\/doi.org\/10.1002\/jmv.29693 (2024).","journal-title":"J. Med. Virol."},{"key":"74729_CR21","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.5624","volume":"32","author":"P Trillenberg","year":"2023","unstructured":"Trillenberg, P., Sprenger, A. & Machner, B. Sensitivity and specificity in signal detection with the reporting odds ratio and the information component. Pharmacoepidemiol. Drug Saf. 32, 910\u2013917. https:\/\/doi.org\/10.1002\/pds.5624 (2023).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"74729_CR22","doi-asserted-by":"publisher","first-page":"e29792","DOI":"10.1002\/jmv.29792","volume":"96","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967\u20132023: a comprehensive analysis of the international pharmacovigilance database. J. Med. Virol. 96, e29792. https:\/\/doi.org\/10.1002\/jmv.29792 (2024).","journal-title":"J. Med. Virol."},{"key":"74729_CR23","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0203","author":"K Lee","year":"2024","unstructured":"Lee, K. et al. Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multi-nationwide cohort study from South Korea, Japan, and the UK. Clin. Mol. Hepatol.https:\/\/doi.org\/10.3350\/cmh.2024.0203 (2024).","journal-title":"Clin. Mol. Hepatol."},{"key":"74729_CR24","doi-asserted-by":"publisher","unstructured":"Park, G., Jung, H., Heo, S. J. & Jung, I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life (Basel) 10\u00a0https:\/\/doi.org\/10.3390\/life10080138 (2020).","DOI":"10.3390\/life10080138"},{"key":"74729_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-021-27631-8","volume":"13","author":"LS Nguyen","year":"2022","unstructured":"Nguyen, L. S. et al. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nat. Commun. 13, 25. https:\/\/doi.org\/10.1038\/s41467-021-27631-8 (2022).","journal-title":"Nat. Commun."},{"key":"74729_CR26","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux, C. et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat. Med. 29, 3100\u20133110. https:\/\/doi.org\/10.1038\/s41591-023-02591-2 (2023).","journal-title":"Nat. Med."},{"key":"74729_CR27","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1038\/s41467-024-48825-w","volume":"15","author":"Y Choi","year":"2024","unstructured":"Choi, Y. et al. Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan. Nat. Commun. 15, 4499. https:\/\/doi.org\/10.1038\/s41467-024-48825-w (2024).","journal-title":"Nat. Commun."},{"key":"74729_CR28","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","volume":"33","author":"LH Mart\u00edn Arias","year":"2015","unstructured":"Mart\u00edn Arias, L. H., Sanz, R., S\u00e1inz, M., Trece\u00f1o, C. & Carvajal, A. Guillain-Barr\u00e9 syndrome and influenza vaccines: a meta-analysis. Vaccine 33, 3773\u20133778. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.013 (2015).","journal-title":"Vaccine"},{"key":"74729_CR29","doi-asserted-by":"publisher","first-page":"1078197","DOI":"10.3389\/fimmu.2023.1078197","volume":"14","author":"M Yu","year":"2023","unstructured":"Yu, M., Nie, S., Qiao, Y. & Ma, Y. Guillain-Barre syndrome following COVID-19 vaccines: a review of literature. Front. Immunol. 14, 1078197. https:\/\/doi.org\/10.3389\/fimmu.2023.1078197 (2023).","journal-title":"Front. Immunol."},{"key":"74729_CR30","doi-asserted-by":"publisher","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","volume":"5","author":"KE Hanson","year":"2022","unstructured":"Hanson, K. E. et al. Incidence of Guillain-Barr\u00e9 Syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Netw. Open 5, e228879. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8879 (2022).","journal-title":"JAMA Netw. Open"},{"key":"74729_CR31","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jama.2021.16496","volume":"326","author":"EJ Woo","year":"2021","unstructured":"Woo, E. J. et al. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February\u2013July 2021. Jama 326, 1606\u20131613. https:\/\/doi.org\/10.1001\/jama.2021.16496 (2021).","journal-title":"Jama"},{"key":"74729_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamaneurol.2023.5208","volume":"81","author":"AG Willison","year":"2024","unstructured":"Willison, A. G. et al. SARS-CoV-2 vaccination and neuroimmunological disease: a review. JAMA Neurol. 81, 179\u2013186. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5208 (2024).","journal-title":"JAMA Neurol."},{"key":"74729_CR33","doi-asserted-by":"publisher","first-page":"e2253845","DOI":"10.1001\/jamanetworkopen.2022.53845","volume":"6","author":"WE Abara","year":"2023","unstructured":"Abara, W. E. et al. Reports of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the United States. JAMA Netw. Open 6, e2253845. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.53845 (2023).","journal-title":"JAMA Netw. Open"},{"key":"74729_CR34","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3201\/eid2712.211634","volume":"27","author":"SC Shao","year":"2021","unstructured":"Shao, S. C. et al. Guillain-\u200bBarr\u00e9 syndrome associated with COVID-19 vaccination. Emerg. Infect. Dis. 27, 3175\u20133178. https:\/\/doi.org\/10.3201\/eid2712.211634 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"74729_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.autrev.2016.09.022","volume":"16","author":"S Esposito","year":"2017","unstructured":"Esposito, S. & Longo, M. R. Guillain-Barr\u00e9 syndrome. Autoimmun. Rev. 16, 96\u2013101. https:\/\/doi.org\/10.1016\/j.autrev.2016.09.022 (2017).","journal-title":"Autoimmun. Rev."},{"key":"74729_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/brain\/awac067","volume":"146","author":"RYS Keh","year":"2023","unstructured":"Keh, R. Y. S. et al. COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: analyses using the National Immunoglobulin Database. Brain 146, 739\u2013748. https:\/\/doi.org\/10.1093\/brain\/awac067 (2023).","journal-title":"Brain"},{"key":"74729_CR37","doi-asserted-by":"publisher","first-page":"e2035","DOI":"10.1212\/wnl.0000000000207900","volume":"101","author":"H Bishara","year":"2023","unstructured":"Bishara, H. et al. Association between Guillain-Barr\u00e9 syndrome and COVID-19 infection and vaccination: a population-based nested case-control study. Neurology 101, e2035\u2013e2042. https:\/\/doi.org\/10.1212\/wnl.0000000000207900 (2023).","journal-title":"Neurology"},{"key":"74729_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/wnl.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs, B. C. et al. The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study. Neurology 51, 1110\u20131115. https:\/\/doi.org\/10.1212\/wnl.51.4.1110 (1998).","journal-title":"Neurology"},{"key":"74729_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","volume":"10","author":"B van den Berg","year":"2014","unstructured":"van den Berg, B. et al. Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 10, 469\u2013482. https:\/\/doi.org\/10.1038\/nrneurol.2014.121 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"74729_CR40","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki, N. & Hartung, H. P. Guillain-Barr\u00e9 syndrome. N. Engl. J. Med. 366, 2294\u20132304. https:\/\/doi.org\/10.1056\/NEJMra1114525 (2012).","journal-title":"N. Engl. J. Med."},{"key":"74729_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1086\/589624","volume":"198","author":"I Nachamkin","year":"2008","unstructured":"Nachamkin, I. et al. Anti-ganglioside antibody induction by swine (A\/NJ\/1976\/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barr\u00e9 syndrome. J. Infect. Dis. 198, 226\u2013233. https:\/\/doi.org\/10.1086\/589624 (2008).","journal-title":"J. Infect. Dis."},{"key":"74729_CR42","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1212\/wnl.0000000000207998","volume":"101","author":"D Bourdette","year":"2023","unstructured":"Bourdette, D. & Silbermann, E. What are the risks of Guillain-Barr\u00e9 syndrome after SARS-CoV-2 infection and COVID-19 vaccination?. Neurology 101, 875\u2013876. https:\/\/doi.org\/10.1212\/wnl.0000000000207998 (2023).","journal-title":"Neurology"},{"key":"74729_CR43","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1056\/NEJMra1208802","volume":"370","author":"HV Fineberg","year":"2014","unstructured":"Fineberg, H. V. Pandemic preparedness and response\u2013lessons from the H1N1 influenza of 2009. N. Engl. J. Med. 370, 1335\u20131342. https:\/\/doi.org\/10.1056\/NEJMra1208802 (2014).","journal-title":"N. Engl. J. Med."},{"key":"74729_CR44","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","volume":"38","author":"ER Miller","year":"2020","unstructured":"Miller, E. R., McNeil, M. M., Moro, P. L., Duffy, J. & Su, J. R. The reporting sensitivity of the vaccine adverse event reporting system (VAERS) for anaphylaxis and for Guillain-Barr\u00e9 syndrome. Vaccine 38, 7458\u20137463. https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.072 (2020).","journal-title":"Vaccine"},{"key":"74729_CR45","doi-asserted-by":"publisher","first-page":"e2003","DOI":"10.1002\/rmv.2003","volume":"28","author":"A Sadiq","year":"2018","unstructured":"Sadiq, A., Bostan, N., Yinda, K. C., Naseem, S. & Sattar, S. Rotavirus: genetics, pathogenesis and vaccine advances. Rev. Med. Virol. 28, e2003. https:\/\/doi.org\/10.1002\/rmv.2003 (2018).","journal-title":"Rev. Med. Virol."},{"key":"74729_CR46","doi-asserted-by":"publisher","unstructured":"Abdelmoneim, S. A. et al. COVID-19 vaccine booster dose acceptance: systematic review and meta-analysis. Trop. Med. Infect. Dis. 7https:\/\/doi.org\/10.3390\/tropicalmed7100298 (2022).","DOI":"10.3390\/tropicalmed7100298"},{"key":"74729_CR47","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","volume":"36","author":"O World Health","year":"2018","unstructured":"World Health, O. BCG vaccine: WHO position paper, February 2018\u2014recommendations. Vaccine 36, 3408\u20133410. https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.009 (2018).","journal-title":"Vaccine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74729-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74729-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74729-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T16:59:35Z","timestamp":1752771575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74729-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74729"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74729-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval for the use of confidential and electronically processed patient data was granted by the Institutional Review Board of Kyung Hee University and the Uppsala Monitoring Centre (WHO Collaborating Center).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"24561"}}